Osiris Therapeutics, Inc. Common Stock
OSIR
OSIR was delisted on the 16th of April, 2019.
11 hedge funds and large institutions have $6.74M invested in Osiris Therapeutics, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 53 closing their positions.
75% less capital invested
Capital invested by funds: $27.5M → $6.74M (-$20.7M)
83% less funds holding
Funds holding: 64 → 11 (-53)
92% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 53
99% less call options, than puts
Call options by funds: $1K | Put options by funds: $139K
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$6.19M |
| 2 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$553K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$152K |
| 4 |
FPF
FNY Partners Fund
New York
|
+$86.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.54M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$2.45M |
| 3 |
Renaissance Technologies
New York
|
-$2.37M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.41M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$1.17M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SO
51
STRS Ohio
Columbus,
Ohio
| – | -$38K | -7,900 | Closed |
|
52
KBC Group
Brussels,
Belgium
| – | -$33K | -6,796 | Closed |
|
53
UBS Group
Zurich,
Switzerland
| – | -$28K | -5,694 | Closed |
|
|
DADC
54
D.A. Davidson & Co
Great Falls,
Montana
| – | -$24K | -5,000 | Closed |
|
55
Legal & General Group
London,
United Kingdom
| – | -$25K | -4,959 | Closed |
|
56
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$18K | -3,876 | Closed |
|
57
BlackRock
New York
| – | -$10K | -2,068 | Closed |
|
58
BNP Paribas Financial Markets
Paris,
France
| – | -$5.66K | -1,153 | Closed |
|
59
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$5K | -1,053 | Closed |
|
|
TRCT
60
Tower Research Capital (TRC)
New York
| – | -$5K | -1,011 | Closed |
|
|
LTFS
61
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$2K | -400 | Closed |
|
|
PMFA
62
Plante Moran Financial Advisors
Southfield,
Michigan
| – | -$2K | -350 | Closed |
|
OSIR Hedge Fund Activity: Q1 2017 in Review
11 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q1 2017, worth a combined $6.74M — down 75% from $27.5M a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of OSIR and 4 opened new positions — a net loss of 49 holders — while 4 trimmed existing stakes and 0 added.
The largest buyer was HealthInvest Partners, opening a new position worth an estimated $6.19M. The largest seller was Vanguard Group, exiting entirely with an estimated $3.54M sold.
- 11 institutional investors held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q1 2017, down from 64 in Q4 2016.
- Funds reported $6.74M of Osiris Therapeutics, Inc. Common Stock stock for Q1 2017, down 75% quarter-over-quarter.
- 4 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q1 2017 and 53 closed out, a net change of -49 holders.
- The largest Osiris Therapeutics, Inc. Common Stock buyer in Q1 2017 was HealthInvest Partners, an estimated $6.19M added.
- The largest Osiris Therapeutics, Inc. Common Stock seller in Q1 2017 was Vanguard Group, an estimated $3.54M sold.
Based on aggregated 13F filings for Q1 2017.